Featured Post

What to Know About COVID Pneumonia

Image
tb gold test :: Article Creator Scientists Develop A TB Test & Find A Genetic Vulnerability In Resistant Strains A rapid diagnostic test for tuberculosis (TB) has been approved for the first time by the World Health Organization (WHO). The assay can identify the tuberculosis-causing pathogen Mycobacterium tuberculosis in sputum samples within a few hours. Tuberculosis is a primary cause of death by infectious disease worldwide. The disease is estimated to kill over one million people every year, and is a huge socio-economic burden, particularly in low- and middle-income countries. "High-quality diagnostic tests are the cornerstone of effective TB care and prevention," said Dr. Rogerio Gaspar, WHO Director for Regulation and Prequalification. "Prequalification paves the way for equitable access to cutting-edge technologies, empowering countries to address the dual burden of TB and drug-resistant TB."  M. Tuberculosis c...
- Post a Comment

Aradigm Announces Submission of Responses to EMA Day 120 Questions and Meeting with FDA - Business Wire

HAYWARD, Calif.--()--Aradigm Corporation (OTCQB: ARDM) (“Aradigm” or the “Company”) submitted responses to the European Medicines Agency (EMA) Day 120 questions on 23 January 2019. The due date for response to the questions was 25 January. The submission of the responses to the questions triggers the restart of the regulatory clock. As part of the EMA regulatory review calendar for marketing authorization application submissions to the EMA for approval, Aradigm will expect a Day 180 List of Outstanding Issues in late March. The clock will stop again until Aradigm responds to those issues, usually within thirty to sixty days. One month later, Aradigm could expect an opinion by the Committee for Medicinal Products for Human Use (CHMP) to our request for approval or a presentation to the CHMP during a formal hearing, which will be followed by the CHMP opinion a month later.

As previously announced, a clinical US Food and Drug Administration (FDA) meeting took place on 25 January 2019, with formal minutes expected within a month.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Aradigm is currently in Phase 3 development of Apulmiq (an investigational proprietary formulation of ciprofloxacin for inhalation) for the treatment of patients with NCFBE and chronic lung infection with P. aeruginosa. Aradigm's inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

About Non-Cystic Fibrosis Bronchiectasis

NCFBE is a severe, chronic and rare disease characterized by abnormal dilatation of the bronchi and bronchioles, frequently associated with chronic lung infections. It is often a consequence of a vicious cycle of inflammation, recurrent lung infections, and bronchial wall damage. NCFBE represents an unmet medical need with high morbidity and mortality that affects more than 150,000 people in the U.S. and over 200,000 people in Europe. There is currently no drug approved for the treatment of this condition.

Forward-Looking Statements

Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including the risk that Apulmiq may not receive regulatory approval or be successfully commercialized, as well as the other risks detailed from time to time in the Company’s filings with the Securities Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 23, 2018, and the Company’s Quarterly Reports on Form 10-Q.

More information about Aradigm can be found at www.aradigm.com.

Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation. Apulmiq is a registered trademark of Grifols, S.A.



http://bit.ly/2G96DN4
-

Comments

Post a Comment

Popular Posts

Preventing, controlling spread of animal diseases focus of forum at Penn State - Pennsylvania State University

Image
UNIVERSITY PARK, Pa. — An outbreak of the highly pathogenic avian influenza virus in poultry in 2014-15 resulted in the destruction of more than 50 million chickens and turkeys in the U.S., causing billions of dollars in economic loss. This animal disease outbreak — the worst in U.S. history — is one example of how devastating a foreign animal disease can be to animal agriculture and the country's economy. The resurgence of avian influenza in multiple states, including Pennsylvania, is once again bringing the importance of preventing animal diseases to the forefront, noted Suresh Kuchipudi, clinical professor of microbiology in Penn State's College of Agricultural Sciences. Exploring the emergence, spread and control of animal infectious diseases such as avian influenza was the focus of the inaugural Emerging Animal Infectious Disease Conference held Nov. 29-Dec.1, 2021, at Penn State. It was hosted by the College of Agricultural Sciences, the Pennsylvania Department of A...
Read more

Model Monday's: Diana Moldovan

Image
dented can botulism :: Article Creator Three Canadians Sickened In France's Botulism Outbreak Are From Quebec: PHAC The Public Health Agency of Canada has confirmed that the three Canadians who fell ill in a botulism outbreak in France are from Quebec. They're among at least 12 people who have suspected botulism after eating sardines prepared and served at Tchin Tchin Wine Bar in Bordeaux, France. The food was eaten between Sept. 4 and Sept. 10. The Associated Press has reported that some patients have been released from hospital, but most of them are in intensive care or critical condition. Canada's public health agency says it cannot divulge the condition of the patients from Quebec because it is considered private health information. Other tourists from the U.S., Ireland, Germany and Spain were among those sickened. One patient, who was not from Canada, has died. France's public health agency is leading the investigation...
Read more

“Live Coronavirus Map Used to Spread Malware - Krebs on Security” plus 1 more

Image
“Live Coronavirus Map Used to Spread Malware - Krebs on Security” plus 1 more Live Coronavirus Map Used to Spread Malware - Krebs on Security Posted: 12 Mar 2020 05:12 PM PDT Cybercriminals constantly latch on to news items that captivate the public's attention, but usually they do so by sensationalizing the topic or spreading misinformation about it. Recently, however, cybercrooks have started disseminating real-time, accurate information about global infection rates tied to the Coronavirus/COVID-19 pandemic in a bid to infect computers with malicious software. A recent snapshot of the Johns Hopkins Coronavirus data map, available at coronavirus.jhu.edu. In one scheme, an interactive dashboard of Coronavirus infections and deaths produced by Johns Hopkins University is being used in malicious Web sites (and possibly spam emails) to spread password-stealing malware. Late last month, a member of several Russian language ...
Read more